Suggestions
Laura Hamel
Postdoctoral Research Fellow at St. Jude Children's Research Hospital
Professional Background
Dr. Laura Hamel is a remarkable postdoctoral research fellow currently making significant contributions to the field of pediatric oncology at St. Jude Children's Research Hospital in Dr. Liqin Zhu's laboratory, part of the Department of Pharmaceutical Sciences. Laura's current research revolves around the characterization of pediatric liver cancer using advanced 3D cell culture techniques. Her efforts not only aim to provide a deeper understanding of this challenging disease but also include conducting high-throughput drug screens designed to identify effective therapeutic agents for young patients. This innovative approach to cancer research marks a pivotal step toward improved treatment options for children facing such formidable health challenges.
Before her tenure at St. Jude, Dr. Hamel gained invaluable experience during her PhD studies at the University of South Florida under the mentorship of Dr. Robert Deschenes. Her doctoral work focused on molecular medicine, culminating in pioneering publications. Notably, she developed a novel fluorescence-based assay to monitor the autopalmitoylation of zDHHC proteins, which has applications in high-throughput screening environments. The results of her research were published in acclaimed journals, including "Analytical Biochemistry" in 2014 and "Comb Chem High Throughput Screen" in 2016, showcasing her expertise in biochemical assay development and drug discovery.
Laura's impressive background also includes a research fellowship at the Technische Universität Braunschweig in Germany, where she had the opportunity to screen organometallic compounds for anti-cancer activity. Her findings during this time were critical contributions to the scientific understanding of organometallic therapies and were published in several respected journals between 2010 and 2013, including "Organometallics" and the "Journal of Organometallic Chemistry." This early work laid the foundation for her subsequent advancements in drug development, embedding her deep understanding of material interaction with biological systems.
In addition to her extensive research, Dr. Hamel possesses a rich educational background. She holds a Bachelor's degree in Biochemistry from the University of New Hampshire and a Master's degree in Pharmacology and Toxicology from the University of Rhode Island. Her Master’s research focused on the activation and translocation of the Constitutive Androstane Receptor in human hepatocytes, with results published in "Toxicology Letters" in 2010. This breadth of educational experiences not only expanded her technical skills but also solidified her foundational knowledge in pharmacology and toxicology, integral to her research pursuits.
Education and Achievements
- High School Diploma from Mount Ararat High School
- Bachelor of Science in Biochemistry from the University of New Hampshire
- Master’s Degree in Pharmacology and Toxicology from the University of Rhode Island, where she collaborated with Dr. Matthew A. Stoner on significant research into hepatocyte metabolism
- Ph.D. in Molecular Medicine from the University of South Florida, including impactful research on zDHHC proteins and their role in high-throughput screening for drug discovery
Throughout her career, Dr. Hamel has displayed exceptional proficiency in various laboratory techniques and methodologies. Her specialties include immortal cell culture lines, primary human cell lines, yeast, and mouse model systems. She is highly skilled in Western blotting, RT-PCR, lenti-viral production and delivery, genotyping, as well as protein production and purification. Additionally, Dr. Hamel has expertise in confocal microscopy, cochlear dissections, auditory brainstem response (ABR) testing, immunohistochemistry (IHC), and the development and implementation of high-throughput screening assays. These skills form a solid platform for her ongoing research endeavors.
Achievements
Dr. Laura Hamel's publication record speaks to her dedication and impact in her field. Her cited works focus on the intersection of biochemistry and pharmacology, underscoring her ability to innovate and apply scientific knowledge to real-world medical issues. Some notable publications include:
- "Fluorescence-based assay to monitor autopalmitoylation of zDHHC proteins" - Analytical Biochemistry, 2014.
- "Identifying novel inhibitors of palmitoylation" - Comb Chem High Throughput Screen, 2016.
- Research on organometallic compounds as chemotherapeutics published in Organometallics and the Journal of Organometallic Chemistry in 2010 and 2013.
- Study on Constitutive Androstane Receptor activation in human hepatocytes - Toxicology Letters, 2010.
Beyond her research endeavors, Dr. Hamel also brings valuable work experience as a former Research Assistant at both the University of South Florida and the University of Rhode Island, as well as her time as a Research Fellow in Germany. She started her career in the sciences as a pharmacy technician, fostering not only her technical skills but also developing important customer service skills that enhance her collaborative approach in research environments.
In conclusion, Dr. Laura Hamel's academic and research journey exemplifies a commitment to pushing the frontiers of pediatric cancer research through innovative drug discovery and advanced cellular modeling techniques. Her trajectory reflects a passion for contributing significantly to the understanding and treatment of pediatric liver cancer, and her continued efforts promise to impart a lasting impact in the field. As she progresses in her career, Laura Hamel stands out as an emergent leader in the intersection of molecular medicine and pediatric pharmacotherapy, poised to inspire the next generation of scientists in this vital area of research.